475160-83-9

Basic information

• Product Name: FMOC-4-AMINOBENZYLALCOHOL
• Synonyms: FMOC-4-AMINOBENZYLALCOHOL;(9H-Fluoren-9-yl)methyl (4-(hydroxymethyl)phenyl)carbamate
• CAS NO: 475160-83-9
• Molecular Formula: C₂₂H₁₉NO₃
• Molecular Weight: 345.39
• Mol File: 475160-83-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 520.4±38.0 °C(Predicted)
• Appearance: /
• Density: 1.293±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.05±0.70(Predicted)
• CAS DataBase Reference: FMOC-4-AMINOBENZYLALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-4-AMINOBENZYLALCOHOL(475160-83-9)
• EPA Substance Registry System: FMOC-4-AMINOBENZYLALCOHOL(475160-83-9)

Safety Data

• Hazardous Substances Data: 475160-83-9(Hazardous Substances Data)

Usage

General Description

FMOC-4-aminobenzylalcohol is a chemical compound with the formula C21H19NO3. It is a derivative of benzyl alcohol, with a fluorine-substituted acetyl group attached to the amino group. FMOC-4-AMINOBENZYLALCOHOL is commonly used as a protecting group for amines in organic synthesis. The FMOC group can be easily removed under mildly acidic conditions, allowing for the isolation of the free amine. It is also utilized in the production of pharmaceuticals and biologically active compounds. FMOC-4-aminobenzylalcohol is known for its stability and compatibility with a wide range of chemical reactions, making it a valuable tool in organic chemistry.

Upstream product

• 623-04-1 4-aminobenzenemethanol 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 914094-76-1 (4-chloromethyl-phenyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 

Relevant articles and documents

Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid

Early detection of skin diseases is imperative for their effective treatment. However, fluorescence molecular probes that allow this are rare. The first activatable near-infrared (NIR) fluorescent molecular probe is reported for sensitive imaging of keloi

DIRECTED CONJUGATION TECHNOLOGIES

Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

Synthesis and biological characterization of protease-activated prodrugs of doxazolidine

Doxazolidine (doxaz) is a new anthracycline anticancer agent. While structurally similar to doxorubicin (dox), doxaz acts via a distinct mechanism to selectively enhance anticancer activity over cardiotoxicity, the most significant clinical impediment to successful anthracycline treatment. Here, we describe the synthesis and characterization of a prodrug platform designed for doxaz release mediated by secreted proteolytic activity, a common association with invasiveness and poor prognosis in cancer patients. GaFK-Doxaz is hydrolyzable by the proteases plasmin and cathepsin B, both strongly linked with cancer progression, as well as trypsin. We demonstrate that activation of GaFK-Doxaz releases highly potent doxaz that powerfully inhibits the growth of a wide variety of cancer cells (average IC50 of 8 nM). GaFK-Doxaz is stable in human plasma and is poorly membrane permeable, thereby limiting activation to locally secreted proteolytic activity and reducing the likelihood of severe side effects.